|1.||Dukes-McEwan, J: 4 articles (11/2013 - 03/2005)|
|2.||Häggström, J: 3 articles (11/2013 - 09/2008)|
|3.||Jöns, O: 3 articles (11/2013 - 09/2008)|
|4.||Willis, R: 3 articles (11/2013 - 09/2008)|
|5.||Patteson, M: 3 articles (11/2013 - 09/2008)|
|6.||Kvart, C: 3 articles (11/2013 - 09/2008)|
|7.||Smith, S: 3 articles (11/2013 - 09/2008)|
|8.||Boswood, A: 3 articles (11/2013 - 09/2008)|
|9.||O'Sullivan, M L: 3 articles (11/2012 - 07/2008)|
|10.||Kasanuki, Hiroshi: 3 articles (07/2003 - 05/2002)|
01/01/1997 - "In a multicentre, placebo-controlled, double-blind trial, 8 weeks of treatment with pimobendan 2.5 mg b.i.d., which was suggested to be the optimal dose in a preceding dose-finding study, definitely improved symptoms and signs of heart failure in 52.6% of patients, and New York Heart Association function class in 64.1% of patients. "
05/01/2002 - "Pimobendan resulted in significant improvement in heart failure class when added to standard therapy in this group of dogs with DCM, and may have contributed to improved survival in DPs."
05/01/2002 - "Addition of pimobendan to standard triple therapy was associated with a significant improvement in heart failure class, regardless of breed (P < .02, Mann-Whitney rank sum test). "
05/01/2002 - "Overall, 8 of 10 animals in the pimobendan-treated group, and 1 of 10 animals in the placebo group improved their heart failure status by at least I modified New York Heart Association functional class after initial stabilization (P = .005, Fisher's exact test). "
07/01/2010 - "Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs. "
|2.||Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
01/01/2012 - "Pimobendan (Vetmedin) is an effective treatment for canine chronic degenerative mitral valve disease and dilated cardiomyopathy. "
05/01/2015 - "A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms. "
08/01/1990 - "[Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy]."
05/01/2002 - "A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy."
11/01/2012 - "The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported. "
|3.||Pulmonary Hypertension (Ayerza Syndrome)
11/01/2009 - "Pimobendan is a positive inotrope and vasodilator that may be useful in the treatment of pulmonary hypertension (PHT) secondary to degenerative mitral valve disease. "
08/01/1997 - "These results indicate that pimobendan may be useful in the treatment of patients with secondary pulmonary hypertension."
01/01/2012 - "Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension."
11/01/2009 - "Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs."
01/01/2012 - "In this report, we describe the effects of a palatable customized oral form of pimobendan used with both compounded and commercially manufactured conventional drug therapy to treat degenerative mitral valve disease and pulmonary hypertension in two small dogs. "
05/01/2006 - "Pimobendane was given to Case 2. Ejection fraction was 57% in Case 1 (2nd hospital day) and 33% (6th hospital day), 43% (7th hospital day)and 58% (16th hospital day)in Case 2. The recovery period of left ventricular abnormal wall motion and the medication period were longer in Case 2 showing diffuse hypokinesis than in Case 1 showing takotsubo-like cardiomyopathy."
12/01/1989 - "Acute cardiovascular effects of 5 mg (group I, n = 6) and 10 mg (group II, n = 6) intravenous pimobendan (UDCG 115 BS) were studied by right and left heart catheterizations in patients suffering from idiopathic dilative cardiomyopathy (NYHA II and III). "
12/01/1989 - "Effect of intravenous pimobendan (UDCG 115 BS) on hemodynamics and left ventricular volumes in idiopathic dilative cardiomyopathy."
09/01/2014 - "Control cats (cats with CHF treated during the same period with a regimen that did not include pimobendan) were selected by matching to case cats on the basis of age, sex, body weight, type of cardiomyopathy, and manifestation of CHF. "
11/01/1994 - "Twelve patients with heart failure, New York Heart Association (NYHA) classification II-III, due to ischemic cardiomyopathy, were studied for 1 h after they received 5 mg pimobendan intravenously (i.v.). "
05/01/2015 - "Pimobendan prevented myocardial remodelling in compensated HF and significantly extended life span in both compensated and end-stage HF, but dose-dependently increased sudden death in end-stage HF. "
11/01/2012 - "The median time to the primary endpoint (onset of CHF or sudden death) was significantly longer in the pimobendan (718 days, IQR 441-1152 days) versus the placebo group (441 days, IQR 151-641 days) (log-rank P = 0.0088). "
11/01/2012 - "That chronic oral administration of pimobendan to Dobermans with preclinical DCM will delay the onset of CHF or sudden death and improve survival. "
07/20/2007 - "We found that a positive inotropic agent, pimobendan, which directly increases myofilament Ca(2+) sensitivity, had profound effects of preventing cardiac enlargement, heart failure, and sudden death. "
11/01/2012 - "Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in Doberman Pinschers with preclinical dilated cardiomyopathy (the PROTECT Study)."
|1.||Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)
|7.||Idiopathic pulmonary hypertension
|10.||Cardiotonic Agents (Cardiac Stimulants)
|3.||Drug Therapy (Chemotherapy)
|4.||Cardiac Resynchronization Therapy